Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued

BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008